This study aimed to investigate whether quercetin exerts anticancer effects on oral squamous cell carcinoma (OSCC) cell lines and to elucidate its mechanism of action. These anticancer effects in OSCC cells were assessed using an MTT assay, flow cytometry (to assess the cell cycle), wound-healing assay, invasion assay, Western blot analysis, gelatin zymography, and immunofluorescence. To investigate whether quercetin also inhibits transforming growth factor β1 (TGF-β1)-induced epithelial–mesenchymal transition (EMT) in human keratinocyte cells, HaCaT cells were treated with TGF-β1. Overall, our results strongly suggest that quercetin suppressed the viability of OSCC cells by inducing cell cycle arrest at the G2/M phase. However, quercetin did not affect cell viability of human keratinocytes such as HaCaT (immortal keratinocyte) and nHOK (primary normal human oral keratinocyte) cells. Additionally, quercetin suppresses cell migration through EMT and matrix metalloproteinase (MMP) in OSCC cells and decreases TGF-β1-induced EMT in HaCaT cells. In conclusion, this study is the first, to our knowledge, to demonstrate that quercetin can inhibit the survival and metastatic ability of OSCC cells via the EMT-mediated pathway, specifically Slug. Quercetin may thus provide a novel pharmacological approach for the treatment of OSCCs.

Objectives: In the present study, we aimed to determine the relationship between health literacy and oral health-related indicators in Korean adults. Methods: We used data from 2023, the second year of the 9th period when health information literacy was newly introduced during the National Health and Nutrition Survey, and grouped it using measurement tools of health information literacy. Results: In model 2, which was corrected for sociodemographic characteristics, the number of units required for a fixed prosthesis increased by 0.098 and difficulties with speaking function increased by 0.138 (p<0.05) in the incorrect answer group compared with that of the correct answer group. Conclusions: The ability to understand health information correlated with oral health-related indicators. Therefore, future policies and educational interventions should focus on simultaneously improving health information comprehension and oral health.

Background: The objective of this study was to evaluate how effectively the bioelectric toothbrush can alleviate dentin hypersensitivity (DHS) by using electrostatic forces to remove biofilm from the tooth surface. Methods: This study divided inpatients of a preventative dental clinic between March and October 2023 into the following two groups: a bioelectric toothbrush group (BET, n = 25) and a non-bioelectric toothbrush group (NBET, n = 18) as a control group. This was a randomized double-blind, placebo-controlled trial study. A survey, the number of hypersensitive teeth, the O’Leary index, the visual analogue scale (VAS), and the Schiff Cold Air Sensitivity Scale (SCASS) were also investigated. Results: When fluoride toothpaste was applied with a bioelectric toothbrush, the subjects’ VAS and SCASS scores reflecting symptoms of hyperesthesia significantly decreased over time, as did the number of hypersensitive teeth and the O’Leary index. Moreover, the bioelectric toothbrush was confirmed to be effective in removing dental plaque. Conclusions: Dental clinics must actively promote bioelectric toothbrushes and fluoride toothpaste for patients suffering from hyperesthesia and pain. Furthermore, these items can be suggested as preventative oral care products to patients with potential hyperesthesia.

Objectives: This study aimed to examine the mediating effect of health literacy on the relationship between generalized anxiety disorder (GAD) and problems with oral function among postmenopausal women in Korea. Data were obtained from the 2023 Korea National Health and Nutrition Examination Survey (KNHANES). The findings will inform strategies to enhance health literacy and promote sustainable oral health management. Methods: Data were obtained from the 2023 KNHANES, which was first year to include a health literacy index. Participants were divided into groups based on GAD status. Complex sampling analysis was conducted using IBM SPSS Statistics 21.0, and the PROCESS macro. Model 4. was applied to test the direct, indirect, and total effects of health literacy on the relationship between GAD and oral health problems. Results: After controlling for sociodemographic characteristics and comorbidities, health literacy was found to have a statistically significant mediating effect on the relationship between GAD and both chewing and speaking difficulties. Conclusions: GAD in postmenopausal women was associated with decreased oral function, and health literacy played a mediating role in alleviating this negative effect. It is recommended that oral health education programs that improve both anxiety management and health literacy are developed and implemented.

Background: Oral ulcers (OU) associated with Behçet’s syndrome are often painful, may interfere with the ability to eat and can negatively affect quality of life.^1,2 Apremilast (APR), an oral phosphodiesterase 4 inhibitor, demonstrated efficacy in the treatment of OU associated with Behçet’s syndrome in a phase III, multicenter, randomized, double-blind, placebo (PBO)-controlled study (RELIEF; BCT-002).³ Objectives: To describe the efficacy of APR treatment in improving OU pain associated with Behçet’s syndrome in RELIEF. Methods: Patients were randomized (1:1) to APR 30 mg twice daily (APR 30 BID) or PBO twice daily for a 12-week PBO-controlled phase, followed by a 52-week active treatment extension. Eligible patients were ≥18 years of age and had active Behçet’s syndrome with ≥3 OU at randomization or ≥2 OU at screening and randomization and without active major organ involvement. Clinical improvement in OU was evaluated by the area under the curve for the number of OU through Week 12 (AUC_Wk0-12; primary efficacy endpoint) and by assessments of OU number. Patient-reported OU pain was evaluated by the 100-mm visual analogue scale (VAS). The statistical tests were 2-sided (α=0.05). The proportions of patients achieving the minimal clinically important difference (MCID) and higher rates of improvement, defined as ≥10-mm,⁴ ≥30-mm (3-fold MCID), ≥50-mm (5-fold MCID) improvements in OU pain VAS scores, respectively, were analyzed through Week 12. An ANCOVA model was used to analyze the primary endpoint and assessments of OU number and OU pain (VAS). The proportion of patients achieving improvement in OU pain VAS scores at Week 12 were summarized descriptively. Results: A total of 207 patients were randomized and received ≥1 dose of study medication (APR: n=104; PBO: n=103). At baseline, the mean (SD) number of OU was 4.2 (3.7) in the APR 30 BID group and 3.9 (2.7) in the PBO group, and the mean (SD) OU pain VAS scores were 61.2 (27.6) and 60.8 (26.9), respectively. At Week 12, significantly greater improvements were observed with APR 30 BID vs. PBO in AUC_Wk0-12 (least-squares [LS] mean [SE]: 129.5 [15.9] vs. 222.1 [15.9]; P<0.0001), number of OU (LS mean [SE]: 1.1 [0.2] vs. 2.0 [0.3]; P=0.0003) and OU pain VAS scores (LS mean [SE] change from baseline: −40.7 [3.3] vs. −15.9 [3.3]; P<0.0001). The proportion of patients who achieved the MCID of ≥10-mm improvement in OU pain VAS scores at Week 12 was greater with APR 30 BID vs. PBO; this pattern was also observed for the higher 3- and 5-fold improvements in MCID (Figure 1). Greater proportions of APR 30 BID vs. PBO patients achieved ≥10-mm and ≥30-mm improvements in OU pain VAS scores over 12 weeks. Notably, greater achievement of ≥50-mm improvement in OU pain VAS scores was observed with APR 30 BID vs. PBO as early as Week 1 and maintained up to Week 12 (Figure 2). Conclusion: For patients with active Behçet’s syndrome, APR 30 BID provided significantly greater improvements vs. PBO in OU number and OU pain at Week 12, including the greater proportion of patients achieving MCID and 3- and 5-fold MCID of OU pain in the APR 30 BID group vs. the PBO group. These results indicate a clinically meaningful treatment effect of APR 30 BID on the OU associated with Behçet’s syndrome. References: [1]Kokturk A. Patholog Res Int. 2012;2012:690390. [2]Hatemi G, et al. Ann Rheum Dis. 2008;67:1656-1662. [3]Hatemi G, et al. N Engl J Med. 2019;381:1918-1928. 4. Dworkin RH, et al. J Pain. 2008;9:105-121. Disclosure of Interests: Gulen Hatemi Grant/research support from: BMS, Celgene Corporation, Silk Road Therapeutics – grant/research support, Consultant of: Bayer, Eli Lilly – consultant, Speakers bureau: AbbVie, Mustafa Nevzat, Novartis, UCB – speaker, Alfred Mahr Consultant of: Celgene, Speakers bureau: Roche, Chugai, Mitsuhiro Takeno Speakers bureau: Esai, Tanabe-Mitsubishi – speaker; Celgene Corporation – advisory board, Doyoung Kim: None declared, Melike Melikoglu: None declared, Sue Cheng Employee of: Amgen Inc. – employment; Celgene Corporation – employment at the time of study conduct, Shannon McCue Employee of: Amgen Inc. – employment; Celgene Corporation – employment at the time of study conduct, Sven Richter Employee of: Amgen Inc. – employment; Celgene Corporation – employment at the time of study conduct, Michele Brunori Employee of: Amgen Inc. – employment; Celgene Corporation – employment at the time of study conduct, Maria Paris Employee of: Amgen Inc. – employment; Celgene Corporation – employment at the time of study conduct, Mindy Chen Employee of: Amgen Inc. – employment; Celgene Corporation – employment at the time of the conduct, Yusuf Yazici Consultant of: BMS, Celgene Corporation, Genentech, Sanofi – consultant, Consultant of: BMS, Celgene Corporation, Genentech, Sanofi – consultant